TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI

TME Pharma NV, a biotechnology company, announces a strategic partnership with aimed analytics, an expert in medical data analysis. The goal: to use artificial intelligence to develop new anti-cancer drugs. This collaboration leverages AI to accelerate the drug discovery process and reduce costs, without requiring laboratory testing. TME Pharma CEO Aram Mangasarian highlights the importance of this project in the context of their strategic vision established in December 2024.

The partnership builds on recent technological advances, similar to those that won the 2024 Nobel Prize in Chemistry, to predict the molecular structure of drugs. Patrick Günther, CEO of aimed analytics, is excited to contribute to TME Pharma’s innovative approach to cancer treatment, aimed at discovering more effective therapies. Together, they hope to take a critical step in creating innovative treatments for patients with aggressive cancers.